Wedbush Starts Cubist Pharmaceuticals (CBST) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
New COO Named at Cubist Pharma (CBST)
November 5, 2014 8:38 AM ESTCubist Pharma (NASDAQ: CBST) announced that Patrick Vink, M.D., M.B.A., currently Senior Vice President and General Manager of Cubists International Business, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2015.
In his new role, Dr. Vink will oversee all global commercial, manufacturing, technical operations, international business operations, and alliance management. Dr. Vink will report into Robert J. Perez, Cubists current President and COO who, as announced on October 20, will become the Companys Chief Executive Officer effective January 1, 2015.
Patrick is a distinguished and trusted biotechnology... More
SunTrust Starts Cubist Pharmaceuticals (CBST) at Buy
November 4, 2014 6:43 AM ESTSunTrust Robinson Humphrey initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Buy rating.
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $73.08 yesterday.
... More